Shares mag. recommending this stock this week. Is this going to be our killer this christmas!!!! any comments anyone?????

has anyone shown interest in this share yet???

I have done very nicely out of this share twice previously. Interest this week from shares mag and rumours of good news on top of it being a well run British company is showing in trades.

For you guys : press mention in today's Independent Newspaper.

CeNes Pharmaceuticals improved 0.5p to 8.12p on talk that the biotech may soon have some positive news for investors from trials of its M6G post-operative pain treatment.

http://news.independent.co.uk/business/analysis_and_features/story.jsp?story=550825

Thanks guys, lets hope the news comes very very soon.

I hope so - have been sitting on this one for quite some time -

lots of buys going through today already up 0.62p, looking good for next week maybe 15p by next Friday!!!!!

Gents 0- lots of volume - we have a pick up -is there news coming thru?

UP 0.50p I hope it continues like this for the rest of the week!!!!

does anyone have any idea when will we have the news about the new drug????

Cenes is one of the plays of the week in this weeks share mag. I'm alreay in so hopefully fingers crossed and hope the trial for M6G proves to be a winner!!!!
Anyone else agrees with me?????

Rkausar

I have also held these for quite a while. They have clearly become a favourite with the Shares Mag, which hopefully shouldn't do the SP any harm in the long run. Only problem is having to be patient due to the time it takes to bring new drugs onto the market. Downside is if the trials do not go well, the SP will probably tank! Fingers crossed!!

Regards

PTH

TWO share comments:
One is this Cenes - been there and it's downhill all the way - and so is this further misery as MM take their cut as the punters to and fro?
I don't see a solid "story" here with a clear-cut route to profits for retail shareholders.
Is there any evidence that things are improvi g - or are we seeing a realisation of distant HOPE becomming reality ?
My worry is that this is not unlike the SECOND co.

DREW: So today the chairman resigned - so what? The company's been bought for a song ( although not for more than it was worth!) because management would not get to grips with reality. A firm needs to have a decent home market that at least keeps the business ticking over, providing a dividend to investors for the risk/ er the use of their money - yet Management sat-about hoping their US agents would provide them with an income. Finally the Agent thinks - why am I rushing about to feather the nest of these lasy types? ( So they bought the co.)
Sadly investors have lost big-time. Am I sorry about the loss of one dullard? Not a bit - pity the others didn't move-out whilst there was still a business to run. A candy-floss selling ( from) under Blackpool Tower could not have done worse, indeed they might have been better.
Phew. there, that's it for now.

if shares mag tipped this one i will wait until it reaches 1p in 3/5 weeks time then buy.

looks ike the MM's a re trying to flush some sellers out! Looks good as that means they ae short of stock!!!!

lots of buys going through up 0.13p, hopefully this will continue on Monday!!!!

Monday is Bank holiday

Okay, TUESDAY then!!!!!!

pick pick pick!!!!!

Its a great "Pick" yet again - third time for me - this time I am hanging on as CEN owes me nothing. Just a little wary as all my health shares are flying this morning - think I like the week starting on a Tuesday !! -

Rgds

GC-R

Will Cenes be mentioned again in share mag. this week?????

Yes Cenes has been mentioned again in share mag this week and is up 0.25 today. Going up nice and steadily, thats what we like!!!!!

Any one know when the next set of announcements are due from the Phase 3 trials?

According to todays Share Mag, the Directors are 'in town' next week and may possibly be making an announcement.

PTH

ptholden - thanks for that - i await ANY news with bated breath.

Any news yet anybody??

This share is being recommened three weeks in a row by share mag., then why are everyone selling for the past few days????

got this share on my watch list . rkauser, your opening comment isnt really the best for a biotech company dealing in medicines....is this going to be our killer christmas???lol
still waiting for news about the directors being in town before i make a decision.

Thanks for pointing it out to me bosley!!! It did'nt click until now that you mention it!!! What I meant was is this share really going to fly by Christmas, is there any way I can change the opening comment????

By the way it is steadily going up, so fingers crossed and hope the Directors bring good news!!!

A flurry of sells first thing this morning - what has spooked the punters?

Probably because the Directors didn`t find each other last week.

Maybe they'll find each other when it's time to vote for the level of their own pay rises!

despite the sells overweighing the buys, the price has still gone up, looks likes thing are brewing up guys!!!

better go up i just bought 60,000 at 10.2p!!!
a tip from share mag frommonths ago

Up 0.63p today, is the good news round the corner???

something is rotten here - a 12% move despite sales outweighing buys 3 to 1 ? Are the market makers pushing the price up to flush out sellers because they are short of stock?

I have just been quoted 11.62 to buy just a small quantity and therefore think that all the 11.6 are buys and not sells as reported.
anyone got the current sell price ????

I have noticed that for the past few days, the more and bigger the sells the higher the price is getting. Something is not right somewehere!!!! Who cares as long as this continues It does'nt bother me!!!

Up 1.26 today price now 11.62, if this continues nice and steadily we might be seeing 15p by the end of the week!!!! Goog luck all.

sorry GOOD LUCK ALL!!

According to Iwebsharedealing sell price is showing as 11.25 and buy at 12.00

I do wish the Directors would stop acting like "Ships in the Night"

OOOH look - an upward movement in price on lots of sales - someone wants to flush out sellers and grab their stock - fill ya boots boys!

Th share price is steadily moving up its 0.50p (4.26%) up today. The Directors are taking their time to reveal the results of the trials!!!

Let us hope that they are not going to be as honest as the CEO of PDX who in similar circumstances announced it was a newspaper talk

There is definetly something going on today, lots of buys going through, does someone out there know something I don't know?????

i am one of the buys . wish i had got in when shares tipped them a few weeks ago . it does look very exciting at the moment.looking for 20p by christmas.

Bosley I bought them the first week shares recommeded them and I also topped up today, up 0.63p looking good so far!! Fingers crossed and all the best!!

lets hope as oakapples says that the price movement this week is not anticipating a positive statement that never happens.on a more positive note any good news could take the share price a long way

Rumour circulating their could be an annoucement on Monday. Hence the volume buying this week.

Does anyone know for sure, is there going to be an anouncement tomorrow???

Probably not imho

momentum - wrong!!!!!

I want to know though despite the lioss announced - why is it that there is no 'momentum' off the back of the phase iii results - are [people expecting the worst or have they deliberately delayed the results of the trials to sogften the blow from the financials?

CeNeS Pharmaceuticals PLC
20 September 2004


CeNeS Reports 2004 Interim Results

Cambridge, UK 20 September 2004 - CeNeS Pharmaceuticals plc (AIM: CEN) ('CeNeS'
or 'the Company') today announced its unaudited interim financial results for
the six months ended 30 June 2004.


Operational highlights

M6G successfully completes Phase III trial in post-operative pain (see
separate press release dated today)
CNS 5161 for neuropathic pain entered a Phase II trial.


Financial highlights

Net loss for the first half of 2004 of 2.3m (H1 2003: profit 0.9m
including 3.2m profit on sale of pharmaceutical products).
Cash balances at end of June 2004 of 6.1m (June 2003: 8.2m).


Corporate matters

Alan Smith, Chairman of Acambis Plc and Avlar Bioventures Limited
appointed as a Non-executive Director.
Piper Jaffray Ltd and Nomura International plc appointed nominated
advisor (NOMAD) and nominated broker respectively.



Commenting on the results, Alan Goodman, Chairman of CeNeS Pharmaceuticals plc,
said:


'The Board is delighted to report that CeNeS has continued to successfully meet
its key strategic objectives in 2004.


We are particularly pleased with the announcement today of the positive M6G
Phase III results in post-operative pain. CeNeS retains all global marketing
rights to M6G and is well placed to capture the potential commercial value in
this novel, late stage pain product.

Additionally, CNS 5161 has commenced a Phase II trial in neuropathic pain with
patient recruitment underway. Furthermore, the Company's pre-clinical short
acting sedative and discovery Parkinson's disease programmes are also
progressing in line with expectations. CeNeS owns the global rights to all three
of these programmes.

There is a significant opportunity for CeNeS in realising the clinical and
commercial potential of M6G as an effective analgesic with a good side effect
profile. In light of these positive results the Company is considering its
financing options for taking this product forward, including equity funding and/
or out-licensing.

Overall, CeNeS is building a balanced, focused pipeline which is being
effectively managed by our in-house experts as evidenced by the successful
clinical progress we have made. CeNeS is also encouraged by additional novel
early stage opportunities that are being identified by our discovery team that
fit our focused 'risk-reduced' selection criteria.


The Board is confident that the Company's clear strategic focus coupled with the
excellent progress made to date in 2004 leaves CeNeS well placed to deliver
increased value to shareholders going forward.'



Contact details:

FOR TODAY ONLY:
Mary Clark - Capital MS&L - 0207 903 1000.

After today contact details are:

CeNeS Pharmaceuticals plc
Alan Goodman/Neil Clark
Tel: +44 (0)1223 266466
Fax: +44 (0)1223 266467
Capital MS&L

Mary Clark/Paula Crymble
Tel: +44 (0)20 7878 3181
Fax: +44 (0)20 7878 3184

Review of the six months ended 30 June 2004

what exactly were people expecting from the results? as far as i read it . they dont really have any products on the market , so no revenue , but good potential products have just successfully gone through trials and could be on the market by next year . this is a buy and hold .

B_R

Don't think it really matters. All people will see today are the losses. Results of the Phase III trials although very good news will not generate any income until 2005/2006. CENES is a long term hold, those in now or at lower levels will reap the rewards later, but unfortunately these lower levels may be around for a little while yet, hence the selling. Hang on if you have the patience. All IMHO of course, DYOR etc etc.

Regards

PTH

looking at trades so far today it seems this was one of those , buy on rumour sell on news type, investments .

Just giving these two announcements a little more thought; Classic piece of bad PR. The losses have grabbed the headlines and the Phase III trials are forgotten. Perhaps they should have released the results, let the SP take the hit and then release the good news three or four days later, probably restoring the SP value. Just a thought, never mind, not long until 2006!!

regards

PTH

Taken a hard hit this morning, tend to think it may be this that as spooked holders....................

"In light of these positive results the Company is considering its
financing options for taking this product forward, including equity funding and/
or out-licensing.". Dilution in one form or another. They were looking very good, perhaps we may get a quick recovery. Dont hold but have been tempted.

cheers GF.

might be a good time to get in gf.

I have taken my profits and run (a little reluctantly!) - but I will be back - if it drops to 9p IMHO it will bounce back

tipped again as a buy in shares mag this week . started to creep back up . looks like people have seen the potential. bad pr excersise making the two announcements together i think.

The words to use are not ' bad PR exercise' - amateurish is more like it,
prices move on perception, they need to be a lot slicker about the way they put across news.

Re post 61 - It did and I did - Is it a bit of a worry that Shares Mag recommend it 3 weeks out of 4 ?

Good write up in the Times today, puts into perspective the 'herd mentality' witnessed following the announcemnt of cash raising required to further the company's ambitions.

regards

PTH

The Sunday Times article:

Biotech chief seeks to end years of pain
By Paul Durman
Alan Goodman of CeNeS hoped good results would change his luck, but he still needs more money



ALAN GOODMAN should be used to disappointment. As one of Britains most experienced biotechnology entrepreneurs, he is only too familiar with the ups and inevitable downs that go with the drug-development business.
Goodman was hoping that last week would mark a new beginning for CeNeS, his pain-treatment company that has endured a troubled three years.



My careers on the line, he said, as he prepared to announce results from late-stage trials of M6G, a treatment for post-operative pain.

I started this (treatment) based on work I discovered in 1992. This is the fruit of 12 years work, several millions of pounds, lots of trauma. Nobody else (in UK biotech) has got a compound from initial discovery through to phase III trials.

If weve got a result, I expect the mainline institutions to invest in it, to say: Jesus, theyve done it.

Last Monday, CeNeS duly announced positive results for M6G, a form of morphine developed to avoid causing the same level of nausea and vomiting.

Goodmans City advisers had hoped that shares in CeNeS would jump by as much as 25%. Instead, the shares weakened as the company said it was considering raising further equity to continue the development of its product.

Analysts close to CeNeS insisted that there was nothing alarming in this. Anyone who followed the company would have understood it needed to perform another phase III trial on M6G to compare it with the gold standard of morphine.

However, CeNeS has recently attracted some hot money from private investors who do not want to wait for a share placing. Hence the fall in the price.

CeNeS may need to raise 8m to 10m, or perhaps 15m if it seeks to avoid licensing M6G to international marketing partners.

Given the size of the market in post-operative pain, believers in the firm insist shares in CeNes look bloody cheap at below 10p. That values the company at only 25m.

CeNeS was briefly a stock- market high-flyer a specialist in pain and neurological disease that Goodman and his team built on the foundations of a moribund Scottish biotech company called Core.

His earlier ventures included the firms that became Chiroscience and Acambis two of the larger and more successful biotech companies to emerge in Britain over the past 15 years.

CeNeSs initial rapid progress came to a grinding halt in 2001. Apart from the collapse of investor confidence in biotech stocks, CeNeS found itself caught up in the severe financial problems and controversy afflicting two much larger drug companies, Elan and Bioglan.

CeNeS had licensed key products to Elan and Bioglan, which had previously been seen as highly successful, fast-growing and profitable businesses Elan was once Irelands most valuable company.

But, within months, both businesses started to unravel amid allegations of dubious accounting practices and exaggerated profits. Bioglan, a FTSE 250 company, quickly fell into administration while Elan embarked on a year-long restructuring programme to stave off insolvency.

That was the nightmare, said Goodman. A company with two major partners going bankrupt. Could we survive it or not? That was touch and go.

CeNeS had no choice but to embark on its own painful restructuring closing research facilities, shedding staff and selling off smaller products to concentrate on its pain treatments. The most important of these is M6G.

CeNeS has overcome numerous obstacles, and is close to delivering a valuable product. But Goodman still needs a bit more time and more money to complete the turnround.

looks like the waters have calmed and the price has done the same, anyone got any update apart from the offering to raise cash for phase 111.

Just bought in today ' 7.37 is this the bottom?

I too am in again. Waited for the SP to reach the recent open offer price of 7.50p and like you did a little better. Past performance would suggest it has bottomed!

We need some positve press comment now

just a thought has anyone got experience/opinion of the time frame for the trials. From phase 2 to phase 3 would be nice. obvious fishing for news to be broken.

watcher

Any views on CEN for 2005? Ten-bagger or 100% loss?!

neither I would have thought. CEN's products are widely thought to be good and any positive news would see a big jump. But all bio's seem to have a habit of promising much more than they actually deliver. At the moment I am holding until I see which direction the newsflow is going

whoops

The good news for this one is that it is holding its own (and no its not a w****r !) despite lack of news = that has not historically been the case with CEN. It will explode !!

Explosion upwards would be good. I'm also in OXB which has been nothing but frustration over the last year so hoping for bigger and better things from CEN.

I have got far too many of these for my health. OXB, CEN, SKP, MDW and DEMG but as a package I am in front and always with much potential eh !!

Crikey - does your doctor know about all those?!

bargepole job

Well that was informative.

It was in reply to your post #72 :

"Any views on CEN for 2005? Ten-bagger or 100% loss?!"

Regards

Let us hope that the one buy of 2.5 mil on an otherwise day of much lesser fish getting out is a sign that some big guns are in.

Dil - Happy to hear your view but some kind of reasoning would have been interesting.

Past performance , too many false dawns but good luck maybe this time it'll be different.

The 2.5 million buys on Friday all but gone with 10 to 1 sells at 2 mil plus today from where I am sitting.Maybe someone knows something butI think we will be back to where we started by tomorrow.Another false dawn as you say Dil.At least I'm not the only one hoping.Sitting on a loss but leaving them in the bottom draw.Good luck to all.

Fair enough, although I have a feeling that this one will actually see the sun rise high in the sky...

Going up. My charts tell me it is now time to buy more so I have. Is it a coincidence that OXB also is moving up, similar chart. Time to buy some more OXB I think! Just bought more CEN as my charts tell me the time to buy is now.

Lots of activity - buys currently have it but far too many unknown - results to-morrow - is it to be a belated Christmas present ?

Let's hope so...

If CEN can keep its head above 10p we could be back in business!

queen1 - how long have you been holding - i am just waiting for phase 3 - should be interesting - retirement fund?

Only about a year bharathi_raj. It's a total all or nothing share which, of course, I'm hoping will be "all"!

Me too - i had 2 big knee ops last year- and i kow what morphine can do to your system - if their hopes for the morphine metabolite come off - it could be big!BUt then again watch some big pharma come in and cream the profits off from under them!

CEN has been a very strong perfomer over the last week or so and hopefully will continue to do so. Took up the rights issue at 7.5p and did wonder at the time if it was the correct decision. Up 30% since then so pleased I did. All they have to do now is get back to the price I paid for them in the first place!

PTH

Any one out there know why we have a drop today?

Is there something someone knows that we don't?

this seems very strange?.

Am wondering the same!

time ti get shafted again by some rancid stock manipulator!

Echo Echo Echo - this stock is devoid of news - whens the next anouncement cycle?

So - we get good trials results - and everyone sells - price drops - go fish!!!

Why the hell has the sp dropped on good news????????????????/

I get the feeling with CEN that there is a lot of people wanting to sell for some reason and they keep putting it off as there are so many announcements due out this year.

But everytime the price goes to 10ish and back down again they get jittery and think they have missed out and the next opportunity sell. That's what they did this morning.

It will all seem silly in 6 months.

Interim results out tomorrow, hopefully they will create some much needed momentum for this share. any ideas of what the results may hold?

No idea mvp45 but they do need to get some momentum going again as they seem to have remained lifeless at this price for a very long time.

Will remain flatlined for another 6 months.

That's the 2nd time you've mentioned 6 months adam although the last time was back in June. Why will they remain flatlined until March iyo?

Yep,

There is no news expected until mid 2006 now. We may get an update during the first 1/4 which is why I say 6 months, but it could easily be 9 or 10.

I have sold a third of mine during the last spike, but will hold the rest until the news comes, as it should send these into the 20's.

Well best of luck to you, I and all other holders then. Wake me up when the snows thaw.....

Held these for ages, sold the 7.5p Rights Issue allocation for a nice profit. Hanging onto the rest. Problem is that these trials take forever and intense patience required. Exactly the same with AZM at the moment.

good luck

pth

so tell me - what is going on now?

No idea but positive movement for a change.

From what i can see the movement has been because of large buys. Could be some positive news on the way!

It's coming up to 2006. Cenes' big year. The Traders have their year 2005 profits in their pockets - taking money off those not able to stay in for the long run and now they are thinking of 2006.
Those who stayed the run, and were able to, are about to reap the rewards.
Patience is a virtue demanded of others but seldom employed by the self.

It was related to the completion of a large sell order and positive comment yesterday.


Large CeNes Shr Order May Signal Bottom

Wednesday, December 14, 2005 8:38:46 AM ET
Dow Jones Newswires

1224 GMT [Dow Jones] CeNes Pharmaceuticals (CEN.LN) shares could be close to their lows once the execution of a large sell order is completed, says trader. "Piper Jaffray are clearing up a line of 22M CeNes Pharma that has been about for a while," trader says. "This stock has been dripping into the market for a while and I think this could well mark the lows once any flippers are out of the way." Piper Jaffray not immediately available to comment. CeNes shares have fallen from EUR8.50 since late September. Now they're +1.9% at P6.9p. (PBA/DWE)

Dont know anything about this share, but loads of buying including 500,000 shares bought by the boss.

Still happening, big style but the price doesnt move. Why is that?????

stock hangover! brokers obviously have plenty to get rid of and people who bought cheaper cycling out - give it time for the washout and then watch it motor to 12 within 3 months - prob rest there

stock hangover! brokers obviously have plenty to get rid of and people who bought cheaper cycling out - give it time for the washout and then watch it motor to 12 within 3 months - prob rest there

The Guardian said yesterday

Talk that CeNes Pharmaceuticals (LSE: CEN.L - news) could be given the green light by US regulators to start Phase III clinical trials of its treatment for severe post-operative pain.

Shares recommended Aug 2004 and still the same? Oh dear. Phase 3 my arse. And even then it won't necessarily deliver. Just another aim loser.

although i agree with your analysis, will probably trade 4p-12p over the next 6 months. as ever buy on the cannons sell on the bugles. a merry christmas and a profitable new year to all cen players

All research points to cenes rising in '06. I had the same opinion of seo (+200 per cent in '05) this time last year! IMHO & DYOR of course.

Best wishes to all for the new year.

jtf


Info:- http://www.fillyaboots.com/f7/forum_posts.asp?TID=1880&KW=cenes

NEWS:Talk that an institution is about to announce it has taken a 3% stake, lifts CeNes Pharmaceuticals. Hopefully pushes share price upwards

A nice little snippet of news:

CeNeS Pharmaceuticals said it has been granted a patent on its short-acting sedatives by the European Patent Office (EPO).

The patent covers a series of sedative compounds, including CNS 7056X, which are in pre-clinical development.

The EPO is the first to grant the patent.

The company said national applications are pending in other key territories including the US and Japan.

CeNeS' short-acting sedatives are being developed for use in patients undergoing short diagnostic and surgical procedures.

Check this out Cenes Looks like it is going places this year. Buy now, looks very undervalued

Dr.Neil Clark wallstreet interview 17/3/06
http://www.wallstreetreporter.com/linked.php?id=16769

Cenes Moving gradually up, lot of results out soon. Better get in this share quick befor you miss out. Big institutions in.

Let's hope so - it's been a long time coming!

Cenes 26th May 2006 Research Report available at the site below :

http://www.objectivecapital.co.uk/

http://www.proactiveinvestors.com/

Just found this article.Very promising indeed.
The site is free to register on and to read the article.Useful site for those that have not seen it.

CeNes: Future looks bright.
By William Foss.

Restructuring a publicly listed company is a painstaking and tedious operation. Over the past three years, CeNes, a pharmaceutical junior, has been the subject of an intense restructuring program to get the company refocused on drug discovery. Cenes went under the knife in an attempt to streamline it's pipeline and build up a cash reserve.

Thanks h.hairettin.

Good news from CeNeS, particularly the bit about potential revenue stream. I notice someone jumped in yesterday with a late reported trade this morning. Must be nice to have inside information.

pth

CeNeS Pharmaceuticals PLC
13 June 2006


Data on CeNeS short-acting sedative to be presented at at the American Society
for Anesthesiology meeting, 2006.


Cambridge, UK, 13th June 2006 - CeNeS Pharmaceuticals plc (AIM: CEN) ('CeNeS' or
'the Company') today announced that four abstracts highlighting the profile of
the short-acting sedative, CNS 7056X, have been accepted for presentation at the
American Society for Anesthesiology (ASA) meeting to be held in Chicago on
14-18th October 2006. One of the abstracts has been selected as a high profile
platform presentation.

The data to be presented at the ASA meeting will highlight the very encouraging
pre-clinical profile of CNS 7056X, including new results showing a rapid onset
and offset of sedative action and rapid metabolism by human liver samples. The
compound is being developed primarily as a sedative for short non-surgical and
surgical procedures. In addition, on the basis of these new data, CeNeS is now
evaluating the potential of CNS 7056X for use in the induction and maintenance
of anaesthesia. Pre-clinical studies to evaluate the potential of CNS 7056X in
these additional indications are being undertaken at The University of
Strasbourg, The University of Adelaide and under a Material Transfer Agreement
at a major pharmaceutical company. The evaluation will complete in the second
half of 2006. Extending the development of CNS 7056X to include the induction
and maintenance of anaesthesia could double the estimated potential market
opportunity to over 400m.

CNS 7056X is the lead compound of a series that was assigned to CeNeS from
GlaxoSmithKline in November 2003. Pre-clinical development work is ongoing with
the intention of filing an IND in the U.S. in 2006. Thereafter, CeNeS is
planning to conduct the first proof of concept Phase I study in the U.S., a
major potential market for short acting sedatives.


Neil Clark, Chief Executive, commented: 'The American Society for Anesthesiology
meeting is the largest gathering of anaesthesiologists in the world with up to
18,000 attendees expected. We are delighted to see that data on our short-acting
sedative will be presented at such an important conference. We are also very
excited by the potential of CNS 7056X for the additional indications of
induction and maintenance of anaesthesia. Presenting at this conference will
enable to us to access key opinion leaders and potential global partners of CNS
7056X'

CeNeS. Phase III study of M6G is to go head to head with morphine.. The study will be made double blind in a way that carer nor patient will be aware of which treatment is being given.. Six Euro countries will be involved, giving a total of twenty sites

CeNeS is out to prove that their M6G drug works faster, giving a lower levels of nausea and a fair comparison of pain management. The study will allow patients to self administer a dose of M6G..

In a nutshell CeNeS is after the sales of M6G for post operative pain.. The market could reach 200m PA.. The next stage as I see it is to secure the valuable licensing agreement.. with partners who are able to offer strong marketing off this major drug to be

The interim results are out visit CeNeS website Over the next few months there should be a steady flow of news Any one out there in on this one

I am myway. Have been holding for some time now and frustrated by the lack of newsflow. If that's about to change so much the better. Seems they're pretty confident of M6G......

Hi queen... as far as I see it M6G is the key to the next stage of CEN SP movment.. I feel that so many companies let them selves down through lack of news flow...

Indeed....as long as it's good news flow!!

The proof of the pudding take time out and read the CeNeS PH Plc write-up in last weeks Investors Chronicle M6G the new pain relief drug to-be.. Is now working through its phase III trials.. Look out for data on the trials by the year end or early 2007.

The company is running short of cash, however the late stage trials for M6G and phase II trials for diabetic neuropathic pain drug CNS5161 should come good.. For cash flow as potential partners are keeping their eyes on the trials

Just what are we looking here a possible replacement for morphine.. I will say no more..

I might need some of either product unless something happens positively after all this :-)

There has been a fair amount of trading of CEN shares over the last week.. Today I found out that UBS AG now hold a total of 16,341,340 or 3.66% of the companies issued share capital.. Which is indeed first class news for the private investors.. As a matter of interest UBS has taken profit on some of the position.. However they are still holding 3.66% of the total issue..

An announcement released by London Asia Chinese Private Equity Fund 17th of October 2006 concerning a 2.1 million investment in China Solar, a Chinese solar thermal business.

China Solars core business is the design and manufacture of solar energy buildings in China, based on its patented solar thermal technology.

Simon Littlewood, Executive Director of LACPEF, commented: The Company has patented technology, an experienced management team, a strong research and development programme, and strong support from the Chinese Government. There are significant opportunities for the Company to expand rapidly to take advantage of its strong brand and first-mover advantage, and the increasing emphasis by the Chinese Government on renewable energy sources and improving the quality of life for the poor.

This is yet another investment by LACPEF.. In China from the private equity fund Investors in London Asia should feel the benefit of this investment I am now looking forward to the results of yesterdays meeting in London with LACPEF and representative of the PLUS markets.. Institutional investors, private investors, brokers and the financial presskeep your eyes open..

LDC togther with LACPEF is moving in the right direction visit www.shareclubuk.co.uk to find out all the news flow for the last six months.. To my mind the LDC business is building up along the right line's ... Keep your eyes open on this one...

What will come first, good results and partnership or a fund-raising at discount?

Cen has made the move to appoint JM Finn & Co Ltd., as its joint broker The company is making way for the markets reaction to Phases III results due out end of year for M6G morphine-6-glucuronide as we all are..

Nice little speculative play write-up in Shares Mag this week.

Been away so placed an order earlier this week.
Just checked and looking good, up already.
Got a feeling when the M6G phase III results are out this will fly.

18,218,723 CeNeS shares traded last week to take the SP up to 6.25p All the AOPs at shareclubuk have were full of activity trying to find out why the SP has been going up we know that the phase III M6G study is on-going.. But we can-not find anyother reason why the SP is trading so well.. Any one out there who can give a reason why..?

Will M6G act as a replacement for morphine thats what Peter our 79 year old was saying at this mornings coffee meeting at the OAPs shareclubuk if so then we should be in clover he then when on to say that at the moment we are trading in the red to the tune of just under 500 on our investment with CeNeS.. Just the same as everyone else we are sitting on our hands waiting the results from the M6G trial.. Then we trust that we can turn the loss into profit..

Peter has Parkinsons said he would like also to see some movement on CeNeS COMT inhibitors - Parkinsons Any one has any news as to a possible partner for M6G?

Hi, does anyone have any idea as to the sudden activity here?

No news afa I know so why has the sp jumped after a lot of months of total inactivity and for no apparent reason plus a lot of buys going through.

About to be gobbled up by a product-hungry major???

What has been nice is the steady rise over the last two weeks. Again and again the results for M6G are out very soon. Speculators are picking up the price. Should the results be negative then bye bye Cenes, but positive and hold on tight... This is the moment that I, and probably the majority of other holders have been waiting for. Bring it on!

Not long to wait now, quite exciting, up 20% already but if results of M6G trials are good as expected this will take-off. Tempted to add.

johnny - check out the advfn thread.

Hi, I stopped posting on advfn a long time ago. Too much personal abuse imho. If speculation there why not here?

Johnny: I know what you mean about ADVFN, there are some appalling people post on there. Seems someone on the CEN thread spoke to one of the management (it wasn't Clark) and was given a bullish update, I think good news in Dec was mentioned. I guess word spread and hence the buying.

Looking good, steady daily rises. Monday would have been good for last sub 6p top-up?

Hmmm!! At this rate I should be into profit by xmas!

lol. Yea, i'm in the same position.

Although I cannot speak with authority, I think today's downward move is a good thing. Panic is normal; when one has bought cheap the emphasis is always to make a profit and sell (we all know the feeling). Next, institutional investers (and other larger investors) like to move the market to assert their strenght and divine greater profit by intimidating the more risk adverse investors out of the market and then to buy themselves, i.e.tomorrow. As a Cenes investor I believe M6G - if it passes regulatory control - to be a groundbreaking drug. My wife has recently suffered some physical inconvience and has recourse to morphine and some of it's less developed substitutes, and she shuns them all due to negative side affects. What a benefit M6G could be. But, almost as importantly, what a cure it could be for the flu my self-same wife says I am not suffering from. I could go to work without complaining. I hope the idea doesn't get swallowed up before it gets the chance to fly.

jobibear,interesting comments regarding morphine.Just out of hospital myself after being operated on and got off morphine as quick as i could because of the side affects.When I noticed this new drug from cenes I immediately invested in the shares as fellow patients and medics kept on about affects from morphine.Mind you at the time with no other alternative anything is better than pain.

I agree re the investor psycology Jobibear. I'm at about break-even now on CEN and there is an urge to sell but my view on their potential is the same as the day I bought the shares so why sell now?!

Peter our 79 year old came to our morning coffee meeting at shareclubuk .. For an update on CeNeS as he had noticed that the SP has been moving up from 5.75p on the 13th November to a high of 8.25p trading on 21st November

The word on the street and the Internet message boards is that the Phase III trial of M6G will lead to a major breakthrough for CeNeS in advance of any announcement the SP is starting to act in response to news yet to come We all have a form of post-SP -pain of which only M6G will assist we must keep our eyes open for newsor need we ..? as the SP will tell the full story

And it's plunging so far today so back to where we started from 2 weeks ago :-(

Hold on to your hats ladies and gentlemen!

What a disappointing sp response so far to an extremely positive update.

I agree, queen, but I can't help think there is an awful lot of positioning going on. Again, the big investors are looking to scare away the timid. And there is short term, quick trade profit taking. It keeps the price down. CENES, I am sure and hope, is due for a serious rapid rise up - the tension is certainly there. They are certainly on the radar, but hey, the best laid plans and all that.

PS And Cenes announced a 74 mln share placing to raise 4.82 mln stg to develop its products. What does that do but dilute our original purchase price. I just hope the company is spending our money wisely, and not too many parties celebrating the birth of Christ.

Well, 'tis the season!

Have held these since 10p,would be a great xmas if it recovers!

It is more promising now than when i bought on the back of a tip at thewrongprice.com

I bought in at 8p so inching back towards break-even. But still think there's a long way to go on this one. All or nothing probably. Let's hope for the former!

Hope you are right Queen,have been very tempted to average down but i have enough money invested in these or should i say i would not be comfortable investing more.

Home Log Out Upgrade Our Services My Account Contact Help



Stockwatch Level 2 Portfolio Charts Shares Magazine Research Quote Indices Market Scan Company Zone Traders' Room
NewsWatch Trades Terminal Alerts Stock Screener Heatmaps News Mobile Futures Forward Diary Investors' Room
World Markets Webcast Directory Poker Personal Finance Insurance Forex Casino Credit Cards Sports Exchange MoneyAM Blogs










CeNeS Pharmaceuticals PLC
06 December 2006


CeNeS Pharmaceuticals plc ('the Company')

Director's shareholding

The Company was informed today that Mr Neil Clark, Chief Executive of the
Company, purchased 139,554 ordinary shares of 1p each in the Company at a price
of 7.13 pence per share.

Following this purchase Mr Clark has a beneficial interest in 574,522 ordinary
shares representing 0.1 % of the Company's total issued share capital.

Enquiries
CeNeS Pharmaceuticals plc Neil Clark
01223 266 466


Website:
www.cenes.com



This information is provided by RNS
The company news service from the London Stock Exchange





| Register | Our Services | About MoneyAM | Terms and Conditions | Privacy Policy | Investment Warning | Content Standards | Corporate Solutions | Advertise With Us |
2006 MoneyAM

Two directors buy at 6.95p following placing

Looks like we could go back to 8p. I hear, no confirmation, that a foreign broker has a price target of 12 or 14p. Can't find any info to back this up to be honest and it looks a little high

This still seems to be moving in the right direction. At least Clark has upped his holding, although not by a significant amount!, so perhaps this shows a degree of confidence on his part.

News in late '06 early '07 I believe.

:-)

could be another xenova

LOL!
Price is same as the start of 2002.
Give me some of that new drug.

The Directors must be in the know.. As they have been buying shares as if they are going out of fashion.!!

I understand that the results from CeNeS pivotal Phase III trial are expected in early 2007, then and only then will the market know the true information and value on the product/company. With 4.28m from the pacing of new shares the company will be able to further strengthen its balance sheet ahead of any announcement

Some big buys today. Trading has certainly perked up of late so something is afoot.

Good news expected soon maybe?

Certain the wait will be well worth it long term.

SMALL ARTICLE IN FT.

GLAXO rumor lifts cenes.????????

ARE WE READY FOR TAKEOFF?

Capetown

Could you e me the article? I know you will infringe copywrite if you paste it here.

Cheers

Whoops!

JOHNNY you have mail

capetown

Hi, Thanks for that. I must confess to being a little dubious about rumours even when they appear in the FT but if Glaxo is showing interest ..... who knows?

The sp is starting to look a lot healthier. Lets hope for good news in January

Cheers

i'm a little behind the game on this one, but happy to be back in since exit in late january. a little short profit from idd. out of the frying pan into the fire??!!

Just topped up.

I, although in moments constantly unsure (and more constantly wrong), believe today's slight move up to be a good indicator of CENES. Previous downward movement in the FT100 index has indefinitely meant a downward movement in CENES price (despite changes with CENE's own market value). However today's FT100 dip of 0.7% (46.5pts) was bettered by CENES who went up by 3.28% (0.25pts). Although aware of some the dynamics of market price and some associated ideas, I believe CENES up spike marks a recent and significant anomoly. However DYOR.

have you been drinking jobi?

I was, and I shall be tonight. Seasonal Greetings one and all. & CENES post those results and put me out of my misery.

And to you Jobi. Have a good night.I'm sure CEN will buy you a drink!

Onward & upwards.

Although this time last year the sp headed north & fell back. If we have some good news as expected this month, we should see some exceptional gains this year.

Best wishes to & good luck to one & all for '07.

Added some more yesterday. Hopefully news soon.

CEN could blow any day now.

M6G results probably within 4 weeks imo.

Objective Capital gave CeNeS a Fair Value of 27p last month:

http://www.proactiveinvestors.co.uk/registered/research/objective-cenes-dec06.pdf

Bless them!

CEN said it could receive up to 5 mln usd in milestone payments over the next few years if trials of its experimental smoking cessation drug, being carried out by a licensee, prove successful.

The group out licensed the selective dopamine D1 receptor antagonist, called ADX10061, to Addex Pharmaceuticals in 2002. The group has now started a phase IIa study in the US, and positive results will trigger the payments to CEN.

The company would also receive annual royalties on sales, should ADX10061 reach the market.

'Whilst we are not guaranteed success from any of our carried interests the chance of realising a financial return from Addex is much increased as a result of them commencing this phase II trial,' CEN chief executive Neil Clark said in a statement.

Hi queen1 Your post is indeed good news for the company and the investors

The big news should be out soon.. CeNeS M6G022 Phase III study on treatment with either M6G or Morphine. Effective analgesic could result in lower levels of nausea in patients receiving M6G compared to those receiving morphine. Keep your eyes on this company.

Indeed myway - They've steadied over 8p which they haven't done for a couple of years now so my eyes are firmly fixed on next moves!

This is from the CeNeS site. The results could be announced anytime

Phase III trials of M6G

CeNeS is also pleased to announce that it has successfully completed patient recruitment in its pivotal Phase III trial with M6G in Europe (Study M6G022) for the treatment of post operative pain. The study enrolled over 500 patients at 24 centres in six countries. Results from the study are expected in early 2007.

J

CeNeS 5 February 2007 The Goldman Sachs Group, Inc. ("GS Inc."), had an interest in 38,960,863 ordinary shares of 1p each in the capital of the Company. This interest arose from a beneficial interest held by Goldman Sachs International Limited, a wholly-owned indirect subsidiary of GS Inc. This shareholding represents 8.1 per cent. of the issued share capital of the Company.

They only buy for profit..

If on 4/12/2007 CEN reported the PIII M6G EU trial complete, they should have received the results by now and be on the verge of publicising.

If the results are good, these could be worth more than 40p.

I telephoned CEN today and was told Neil Clark is on holiday until Friday (this is currently school half-term) so I do not expect any news regarding the Phase 3 M6G results this week.

Maybe next week ?

The good news is out today. M6G successful in phase III European trials.

:-)

12p today maybe. I think end results hit all targets --- 25% improvement over morphine was needed --- got 28% ---- phew! Close but enough for c150m-200m sales -- my guess. That's enough for c12p alone for CEn let alone other pipeline which looks nice too

Get in - come on baby!

Looking very good.

It feels good when the patience starts to pay off. Good luck too all.

J

Superb results today for CEN's M6G in the pivotal European Phase 3 trial, meeting all endpoints.

This almost guarantees the financial security of the Company imo.

The share price is obviously undervalued and should now be quickly rerated as the good news becomes more widely known.

I am holding for a massive upturn during 2007.

Well done CEN, you have actually done it!

Also a massive boost for the credibility of the management and the rest of the pipeline.

Excellent.

Have to say after holding for so long i am shocked at the SP after such stunning news,the saying buy on rumour and sell on news comes to mind,but i missed the boat thinking it would go to at leat 12p,guess i will have to hold for the long term and hope the market wakes up to the MASSIVE potential of CEN.
Good luck to all.

A little surprised too Capetown but let's wait for the shares mags next week

I have no knowledge whether the endpoints were strong enough to ensure that a major player will be interested but seems that the co thinks so.

But likely institutional holder will be using volumes to sell down stake. Goldmans have been selling according to recent news and they still had over 37m shares at last count

Their continued selling would only be good news IMHO

Yes, it's a strange feeling - such fantastic news and yet so little sp activity. They say the market's never wrong but surely in this case.....?!

Lets hope so Queen,if this is anything to go by i am tempted to sell my small stake in IQE,should that sp fall on expected good news.

Here is this mornings email from cenes in full-


CeNeS Pharmaceuticals plc

Successful Phase III results announced on Lead Product M6G
Phase III trial in Europe demonstrates M6Gs benefit compared to morphine in the treatment of post-operative pain


Cambridge, UK, 20th February 2007 - CeNeS Pharmaceuticals plc (AIM: CEN), the Cambridge based biopharmaceutical company, today announces preliminary results of the pivotal Phase III trial (M6G022) of M6G (morphine-6-glucuronide) in over 500 patients with post-operative pain. This study is the largest carried out to date with M6G and has delivered very strong results with M6G showing benefits over morphine in the management of post operative patients. M6G022 demonstrates the unique product profile of M6G with equal analgesia to morphine but with reduced nausea and vomiting.

Phase III trial results

1. M6G matches morphine for analgesic effect

Importantly for a novel pain product, the trial results unequivocally show that M6G is as good as morphine in terms of analgesia achieved in patients up to 48 hours post-operatively. Successful achievement of this first primary endpoint supports data from previous clinical trials of M6G and is an essential component in the product profile of M6G.

2. M6G shows significant reduction in post-operative nausea and vomiting compared to morphine

The trial results confirm the excellent potential of M6G as an analgesic with a clinically significant improved side effect profile compared to morphine. The study results show that patients receiving M6G experienced a 28% reduction in the severity of post-operative nausea and vomiting (PONV) in the key 6 24 hours after treatment (statistically significant, p=0.018).

In addition, the incidence of dry retching/vomiting in the M6G arm compared to the morphine arm in the 24 hour period after treatment was reduced by 32% (statistically significant, p= 0.044). The incidence and severity of post-operative nausea in the M6G arm was 27% less than that observed in the morphine arm in the period 6 24 hours after treatment. This was the second primary endpoint and approached statistical significance (p=0.052).

Morphine formulations are the gold standard treatment for the relief of moderate to severe post-operative pain. A limitation of morphine treatment is often the unpleasant side effects experienced, of which nausea and vomiting are the most common. PONV is rated among patients as one of the most distressing after-effects of surgery and reduces their quality of life.

M6Gs lower propensity to cause nausea and vomiting in the post-operative period strongly supports CeNeS belief in the potential of M6G as a novel product for the treatment of post-operative pain with clear advantages over morphine.


The global market was valued at $1 billion in 2000 and growing at a rate of 6-7%.

3. Safety profile/adverse events

The trial confirmed that M6Gs safety profile is similar to morphine. Aside from nausea and vomiting, the adverse events reported were at levels similar to those experienced by patients receiving morphine in a post-operative setting.

Dr Alexander Binning M.B. Ch.B. FRCA, Consultant Anaesthetist at Western Infirmary, Glasgow and Principal Investigator on M6G022, commented: These data demonstrate that M6G is equivalent to morphine in its analgesic properties. It also shows a clear improvement in managing post-operative nausea and vomiting and has significantly advanced the development of M6G as a potential new drug.

Neil Clark, Chief Executive of CeNeS, commented: These results strongly confirm our belief in the excellent potential of M6G as a novel product for post operative pain. The quality and breadth of the data contained in this large study support M6Gs anticipated product profile. With the completion of this large European study CeNeS is confident that it has a substantial data package that differentiates M6G from morphine which will be attractive to a larger pharma partner to licence. CeNeS intends to file an IND (Investigational New Drug application) for M6G with the FDA in the next few weeks. The data from this trial will also be submitted for publication in a scientific journal in due course.


The successful completion of this large, pan-European study demonstrates the excellence of our clinical development team and the quality of the clinical trial protocol. Following this success we now look forward to working with partners to register M6G as a product in major markets.


M6G022 Study Design
The study involved 24 centres in six European countries and recruited 517 patients. The study was designed primarily to provide key information on a comparison of effective intravenous pain management regimens of M6G or morphine treatment for a minimum of 24 hours (and up to 48 hours) following major abdominal surgery. Morphine is generally accepted as the gold standard drug for use in these circumstances. Initial pain management was achieved by administration of a loading dose and titration of either M6G or morphine to achieve acceptably low levels of pain for the patient to go onto the ward. In the ward, pain management treatment was achieved by patient controlled analgesia (PCA), whereby the patient was allowed to self administer a dose of M6G or morphine as required to control their pain. The study was randomised and double blind so that neither patient nor carer was aware of which treatment was being administered. The main purpose of the study was to demonstrate statistically that:

- treatment with either M6G or morphine, particularly during PCA, results in similar levels of pain management; and

- effective analgesic treatment during PCA results in lower levels of nausea and vomiting in patients receiving M6G compared to those receiving morphine.

In addition, other important side effect, efficacy and safety features were determined throughout the study.


M6G Commercial Strategy
CeNeS has commissioned a number of qualitative market research studies on M6G, which have been carried out by independent market research agencies with extensive experience of the pain market. The outcomes of these studies, involving interviews with clinicians and payers in major markets, support CeNeS view that potential global peak sales of M6G in post-operative pain could reach $400 million. This is underpinned by a clear need for an improvement on existing drugs for moderate to severe pain which do not offer the attractive M6G profile of morphine-like pain relief with reduced side effects.

CeNeS believes that the positive results announced today from M6G022 will enable the Company to secure valuable licensing agreements for Europe and North America with partners able to offer strong specialist marketing, sales and distribution capabilities within the hospital sector. CeNeS intends to explore all opportunities to capture value from any such licensing agreement including the possibility of retaining promotion or co-promotion rights within certain territories.

CeNeS is in discussion with a number of potential partners and is confident that the positive results from M6G022, together with the extensive package of clinical, non-clinical and manufacturing data provides an attractive package for out-licensing.

--ENDS--


There will be a teleconference briefing for analysts and investors today at 9.00am. For details please contact Mo Noonan on +44 (0) 207 831 3113 or mo.noonan@fd.

Suspect that the market is going on the principal of "Show us the Money". Two major steps still need to be overcome to hit the jackpot
1) FDA approval - by no means guaranteed.
2) Licensing deal.
All today has done is to greatly increase the chances of success. If you have belief
this could give you an excellent chance to top-up

Am guessing on institutional seller, but also results are not as good as expected.

Could anyone help on my below assumption by filling in the figures

1. Total Morphine Sales
2. % of people sick when taking morphine

1*2= potential market as would expect CEN drug to be back up if costs more than morphine --- i.e. used as substitute to morphine when patient sick

Anyone know?

Just as well the trials were positive. As if not, the share would have been south of 5p by the look of it

Leaving me in pain and feeling somewhat sick !!! :-O

No gain without pain!

Joined you today on the news, lets hope it has the same run as my ASM who also have a drug in phase three looking for a deal. As you say when the news gets more widely known this is going up.

Driver, could be a really good future for CEN, I've been holding for a couple of years, very small amount but topped up today. I have to take morphine on a regular basis, whilst I have got used to it there are still some side affects and I think that CEN may well have produced an excellent alternative. This could be a real winner.

Kim
I agree the M/Cap is far to small for cen with a drug thats an alternative to morphine I would imagine there are millions of people world wide that suffer side effects and would love to try some thing different if they had the choice.

Yes Driver, the prospects are huge if approval is given, there is still some way to go but it certainly looks good at the moment.

Interesting to speculate that in addition to patients receiving CEN's M6G experiencing a 28% reduction in the severity of post-operative nausea and vomiting, and a 32% reduction in dry retching/vomiting, compared to morphine; the proportion of patients taking M6G who also just "feel better" with M6G in comparison to morphine, would probably be even higher, so the benefits of M6G may be even greater than indicated in the successful headline figures!

There appears to be a large seller causing some of the market makers to hold down the share price, otherwise it looks OK. Hopefully the sells will soon clear and the price will be rerated upwards, particularly now the European Phase PIII M6G results have been positive.

I hope so Ludlow Castle as the SP performance since the announcement has been truly disappointing.

queen1, consider the following:

1) M6G just passed pivotal PIII European trial. Should be on the market in 2008.
2) IND to go directly into USA PIII M6G expected to be filed in next few weeks.
3) Deal for M6G anticipated or take-over of CEN possible.
4) CNS 5161 already in PII and a potential blockbuster.
5) CNS 7056 and COMT inhibitor to enter PI's during 2007. Potential blockbusters.
6) Objective Capital valued CEN at 27p, even before the good M6G PIII results.

A disappointing fall today on relatively small volumes. Still very early days for M6G so I think there is a way to go yet before we see any sp movement.

johnny, the small sellers this week have just been shaken out by the fall in the share price caused by the recent big seller.

Furthermore, M6G has just passed European PIII and is not therefore in "early days" as you say.

4 market makers now blue. The share price could bounce high and fast once the big seller ends imo.

Ludlow, I meant 'early days' in as much as there is yet to be any cash generated. I have been accumulating for twelve months & would hate to see cen swallowed by a t/over just as the products are coming to fruition.

The potential market is huge.

Good luck

The Times (Online)
21st February 2007
Robin Pagnamenta

Synthetic Morphine Trials Give Booster to CeNeS

Shares in CeNeS Pharmaceuticals rose sharply yesterday after the Cambridge biopharmaceutical company announced encouraging final-stage trial results for its synthetic morphine drug, M6G.

Preliminary results of a European trial of 500 patients using the drug for postoperative pain showed it worked as effectively as morphine but with less severe side-effects.

The opiate morphine is one of the most commonly prescribed drugs for relief from postoperative and cancer pain as well as pain associated with trauma but it frequently causes vomiting, respiratory problems and constipation as well as being highly addictive.

The study showed that patients receiving the synthetic version of the drug experienced a 28 per cent reduction in the severity of postoperative nausea and vomiting in the six to 24 hours after treatment.

The global market for a less harmful synthetic version of morphine could be worth as much as $500 million (255 million).

Its a decent late-stage trial result, said Navid Malik, pharmaceuticals analyst at Collins Stewart.
Neil Clark, CeNeS chief executive, said: With the completion of this large European study CeNeS is confident that it has a substantial data package that differentiates M6G from morphine, which will be attractive to a larger pharma partner to licence. The company, which is planning to seek approval from US regulators for the drug in the next few weeks, is currently seeking a licensing partner to market the drug in Europe.

CeNeS was founded in 1997 and is listed on the Alternative Investment Market.The shares rose nearly 3 per cent to 8.625p.

As well as its synthetic morphine drug, the company is developing additional pharmaceuticals for Parkinsons disease and schizophrenia.

Ludlow Castle, my comment was on the market reaction rather than CEN Thanks for the pointers though.

Look at the latest news --- Goldmans sold all their stock on Tuesday -- 7.8% of the co!!--- they were selling before announcement, and took advantage of the good news which bought in volume to rid themselves of a meaningless position for them --- this is a big positive for this stock --- stop losses remain ridiculous in this sort of stock while institutions do not care what price they get once they have decided to rid themselves of it.

See my comment higher up that this is what we could have expected

Confident, yes, good to see the RNS this afternoon confirming that as of 4.30 pm two days ago, our big seller (Goldman Sachs) that was forcing the market makers down, no longer had a notifiable interest in CEN, i.e. their shareholding fell to below 3%. Presumably their holding is now just somewhere between 3% and zero, and they will either have cleared any remaining stock in the last two days, or be on the verge of clearing. Following this and with the recent announcement of successful European PIII M6G results, the share price should climb to its rightful fair value of four or five times the current level.

good that's goldman out the way

Tempting to add again, Goldman might just have provided another buying opportunity on CEN by selling thier large stake. We have EU phase III results now that confirm performnace, next stage is USA. Surely a licencing partner will follow soon to progress this, not to mention the other products in the pipeline. sp is too low IMO.

Agreed Andy and topped up today as a result although its reported as a sell. Imo there's value in this one, that seems to have excaped the market. We can all debate pricing theories, but improved performance must carry weight in the eyes of the ultimate purchasing decision makers.

Eventually this value must out - just a matter of time I would suggest.

andysmith
andy you never got back in on ASM then, CEN should at least be heading in asm's direction having a drug in phase III and also the pipe line as you say.

Driver, didn't get back into ASM, much to my annoyance.
Got bored with sp moving between 18p-23p so took my dosh out which seemed good when they nose-dived to 12.5p last year after Roche pulled out but the strong pipeline of products and continued excellent results has pulled sp higher. Same could be true for CEN although I see that brokers have gone neutral from strong buy? Maybe results of phase III not as convincing as they'd hoped but surely a pharma would be interested in a product as efficient as morphine but without side affects? I'd like to know why the downgrade.

.

Broker Cannacord Adams down-graded as in their opinion the M6G results may not have been significant enough statistically to gain a licensing deal and the trial may have to be repeated. This makes current situation speculative only in terms of timescale, if CEN do have to repeat the phase III trial I guess more money need to be raised, I guess it depends on what view potential licensing partners have?
Next week will be a good gauge of market reaction dependant upon whether Goldman have got rid of all of the stock that they want to, they have <3% but that could be nothing at all or 13m ish.

Andy - There are 3 key results of which one (POINT 3 BELOW) is regarded as potentially not statistically significant;

1. Patients receiving M6G experienced a 28% reduction in the severity of post-operative nausea and vomiting (PONV) in the key 6 - 24hours after treatment (statistically significant, p=0.018).

2.In addition, the incidence of dry retching/vomiting in the M6G arm compared to
the morphine arm in the 24 hour period after treatment was reduced by 32%
(statistically significant, p= 0.044).

3. The incidence and severity of post-operative nausea in the M6G arm was 27% less than that observed in the morphine arm in the period 6 - 24 hours after treatment. This was the second primary endpoint and approached statistical significance (p=0.052).


You will of course note that we are talking about 1% variance here, and that at the end of the day its on the right side (ie 27% better) - even if this result tests again and is netral (ie No improvement/deterioation) then the trial would have succeeded on 2 out of 3 counts, and have no detrimental effect on the 3rd measure.

Surely that is sucess ?

Flackwell, I agree. The Times (21/2/2006) reported the following:

Its a decent late-stage trial result, said Navid Malik, pharmaceuticals analyst at Collins Stewart.

Agreed folks, just establishing why the fall and a downgrade could be the reason however as my mate Driver points out, ASM dived to 12p last year after Roche pulled out of working with them but the quality of the pipeline has seen a rise to 50pish. CEN has the good results, will pusue the US and has other products on test, hence ny comment speculative only in terms of timescale, this will come good and CEN is undervalued IMO.

Investors Chronicle
23rd February 2007 (page 14)

Relief for CeNeS Investors

CeNeS shares rose by 3% to 8.62p after the company announced encouraging data from late-stage trials of morphine replacement M6G. In post-operative patients, the product provided the same quality of pain relief as morphine, but with reduced nausea. However, the shares dipped after Karl Keegan, analyst at Canaccord Adams, downgraded them from buy to hold. He says the nausea reduction was not statistically significant and that CeNeS could have to do another trial.

Tip Update

The shares are below our buy tip (10p, 20th May 2005). But, with the potential for a licensing deal, they remain a speculative buy.

..........................

Personally, I now consider OXB to be the best punt on prospects of a deal.

I bet CeNeS's management and shareholders are livid with Karl Keegan's (Canaccord) comments about a possible further PIII trial (following the European PIII M6G results last week) although he appears to be correct.

right, all this crap is now history! are any partnering deals gonna happen,if not cen will tread water.

The market gets what its been waiting for,and its down 30%,i give up.

Annoyingly (maybe not now), my trailing stop banked the profit for me Thursday and I was looking to buy them back and add at the same time. Too busy Friday however glad I waited as it looks like the market does not like the comments and downgrades and the possibility of delays to market. I still believe that CEN will deliver M6G, lets face it, it is as good as morphine and without the side affects. I have researched over the weekend and the report has been put out on many pharmaceutical and clinical websites. Staying put for now whilst this bottoms out, I've learnt before that you cannot beat the market with your own loyalty but I will be back in once the dust settles.

andysmith,i will hold and add @6p,think thats the best option for me,feel sorry for those that bought recently @9 on the day of the RNS,i agree long term it should be a winner.

It would appear though that whilst Goldman are selling that others are adding to their holdings. Two recent RNS, Gartmore now exceeded 10% and Unniverstites Superannuation exceeded 3%. Maybe this is why the drop, Goldman may still have >10m shares and the buyers want a cheaper price just in case there are delays? Watching closely here but I have time after this fall. CEN will deliver M6G if as good as reported, the side affects of morphine are not good. I think CENES need to come out and respond to the comments of Karl Keegan and advise whether another phase III for Europe is required before licensing deals are likely.

Announcement today: Gartmore declare a 10.3% (49,977,758 shares) holding in CEN.

True Ludlow,but its had NO impact on the SP!!,
Market knows more than i do.

.

Hope you are right!!,but for now its not good.

capetown, the 32% reduction in dry retching/vomiting for European PIII M6G in comparison to morphine was still an encouraging result. Have you sold?

Ludlow,i agree with all that you are saying,I have NOT sold out,just simply stating that the sp is grimm,i will add @6 p to my other holding and wait.

CeNeS Investor Chronicle 23rd February. I read with interest the report page 14 on CeNeS.. However I disagree with Karl Keegan, analyst at Canaccord Adams who has downgraded from buy to hold.. As he says the nausea reduction was not statistically significant and that CeNeS could have to do another trial..

Trials delivered Stong results with CeNeS saying that M6G showed significant reduction in post operative nausea and vomiting compared to morphine.. That on its own is a major benefit to patients.. Its bad enough being in pain.. Reduction of nausea and vomiting is a key factor.. Thank you CeNeS for all the trials that your company has undertaken to prove that M6G is the better drug.. For pain relief with reduced side effects..

With the Gartmore investment CeNeS will soon bounce back...

So why has the share price bombed again this morning

CEN Level 2:

5 market makers blue.

capetown
I agree not worried I will also add if it dips any lower.

Much better day today,anothe few mill buys and we might get a tick up.

Having spoken to the CEN, my understanding is they have other statistically significant data that supports a reduction in nausea but they did not choose those particular data measurements as one of the two primary endpoints. Obviously the statistically significant 32% reduction in retching/vomiting, which was the other primary endpoint, still stands.

barclays now have 14% holding!!!!

Nice to see some good news on a s**t day!

.

Objective Capital have issued a new report on CEN saying the failure to meet the primary endpoint for PIII M6G in the nausea indication, will necessitate a further Phase 3 trial (probably as part of a US Phase 3 trial) and delay launch until 2010.

Looks like 4.50/5.oo back on the cards then,and back to bottom draw.

Alan Goodman, Chairman of CeNeS, said:

"CeNeS has taken a major step forward in the development of M6G and is now well
placed to successfully commercialise its lead asset. The partnering process has
begun and the Company is well positioned to deliver significant value to
shareholders in the near-term."

From the finals. We shall see. Only time will tell.

Agree long term bottom drawer!

Some news-

FDA approves IND on Lead Product M6G

Cambridge, UK, 26th April 2007 - CeNeS Pharmaceuticals plc (LSE: CEN), the Cambridge based biopharmaceutical company, today announces that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for the clinical development of morphine-6-glucuronide (M6G), its novel drug for the treatment of post-operative pain. Earlier this year, CeNeS announced results of a Phase III study of M6G in Europe in over 500 patients with post-operative pain. The study demonstrated that M6G provided equivalent pain relief to morphine but induced significantly less post-operative nausea and vomiting (PONV).
The opening trial under this IND will be a Phase I pharmacokinetic study in volunteers. This study is required by the FDA as is an additional pre-clinical toxicology analysis before progressing to Phase III trials. CeNeS is currently completing the protocol design of the first US Phase III trial. The filing of the IND enhances the package of data already available to potential US partners for review.
Neil Clark, Chief Executive of CeNeS, said:

"The FDAs approval of our IND application for M6G is a major landmark in CeNeS clinical development programme. North America is an attractive market for our drug candidate and M6G is clearly positioned to be a genuine alternative to standard morphine therapy."

More good news then - but if the SP history of CEN is any guide I suspect we'll head south from here!

Not a one-trick pony:

CeNeS Pharmaceuticals PLC said the data from an independent study published in the scientific journal Synapse supports and extends the company's original findings with its potential treatment for neuropathic pain, CNS 5161.

The biopharmaceutical company said it plans to test the drug in further phase II trials in cancer pain and neuropathic pain later in the year.

Some news.

UK, 4th May 2007 - CeNeS Pharmaceuticals plc (LSE: CEN), the Cambridge based biopharmaceutical company, notes the publication of an independent study in the respected scientific journal 'Synapse'* on its Phase II NMDA antagonist, CNS 5161. CeNeS is developing CNS 5161 as a potential treatment for neuropathic pain. The independent study builds on the work that CeNeS has already undertaken with CNS 5161.

In the study reported in 'Synapse', Dr Anat Biegon and her group at the Brookhaven National Laboratory, New York, USA, have studied a radioactively labelled version of CNS 5161. They have shown that CNS 5161 is a selective and high affinity NMDA receptor antagonist with preferential binding to the activated form of the receptor. The group also demonstrated that CNS 5161 penetrates the brain well and can be used to label selectively brain NMDA receptors in vivo. Dr Biegon proposes that a radioactive form of CNS 5161 may be used as an agent to monitor NMDA receptors in the human brain using Positron Emission Tomography ("PET") and notes that "the significance of a selective, validated radiopharmaceutical agent suitable for detecting widespread as well as highly localized changes in the NMDA receptor in the living brain cannot be exaggerated".

Data from Phase I and Phase IIa studies previously carried out by CeNeS have shown that CNS 5161 has analgesic properties in patients with neuropathic pain, but does not induce the severe psychotomimetic side-effects associated with other NMDA antagonists.

Neil Clark, Chief Executive of CeNeS, said:

"The data published in this paper supports and extends our original findings with CNS 5161. It has proved very difficult to develop a PET agent with the properties that make it possible to monitor NMDA receptor activation in the human brain. The profile of CNS 5161 as a selective, high affinity and brain-penetrating agent now make this a possibility. These properties of CNS 5161, together with its low liability to induce side-effects, are the scientific foundation for our clinical development programme of CNS 5161 as a novel treatment for the major neuropathic pain market. We plan to test CNS 5161 in further Phase II trials in cancer pain and neuropathic pain later this year."

*In vitro and in vivo characterization of [3H]CNS-5161. A use-dependent ligand for the N-methyl-d-aspartate receptor in rat brain. Biegon et al., Synapse, volume 61, pages 577-586, 2007.

For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466

JM Finn Geoff Nash Tel: +44(0) 207 628 9688

Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: www.cenes.com

About CNS 5161 A range of primary diseases or conditions such as diabetes, cancer, HIV/Aids and shingles, or surgical procedures such as limb amputation can result in nerve damage which leads to a sustained chronic pain. This neuropathic pain is difficult to treat as traditional analgesics do not provide adequate relief for many patients. Drug treatments for neuropathic pain represent a significant area of unmet medical need and a growing market opportunity that is currently valued at over $2 billion globally. Glutamate (particularly NMDA) receptors have been implicated in the induction and maintenance of neuropathic pain and NMDA antagonists may represent a class of drugs for effective relief of neuropathic pain. CNS 5161 is a blocker of the NMDA ion channel and has completed Phase I and more recently Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain. Two Phase I studies using CNS 5161 administered intravenously have been completed in male volunteers. The first study demonstrated the safety and tolerability of selected doses of CNS 5161 and the second that at a dose of CNS 5161 that was well tolerated, analgesic effects were evident in an experimental model of pain. Two phase IIa studies have been completed giving single dose intravenous infusions of CNS 5161 to patients with long standing intractable neuropathic pain. A total of 48 patients have received CNS 5161; 10 patients in an initial study and 38 patients in a study completed in 2005. Both studies reported analgesic effects of CNS 5161 at doses that were well tolerated by the patients

Some more positive up to date news (Abridged for copyright reasons):-

CeNeS Pharmaceuticals plc

Statistical analysis of the recent Phase III trial on Lead Product M6G shows additional benefits



Statistically significant reduction in sedation during the early post-operative period compared to morphine



Statistically significant reduction in nausea in the female patient population compared to morphine



Cambridge, UK, 8th June 2007 - CeNeS Pharmaceuticals plc (AIM: CEN), the Cambridge based biopharmaceutical company, announces additional data from post-hoc analysis of the recent Phase III trial (M6G022) of M6G (morphine-6-glucuronide) in over 500 patients with post-operative pain. The Phase III data released on 20 February 2007 confirmed M6Gs planned product profile and showed that M6G provided equivalent pain relief to morphine but induced significantly less post-operative nausea and vomiting (PONV).



Sedation



Analysis of the sedation data from the M6G022 trial showed statistically significant reductions in sedation in the M6G group compared to morphine in the first four hours after surgery reaching a reduction of 15% at 4 hours (p=0.007). Discussions with clinicians support the view that this is a clinically important benefit. Opiates such as morphine are well known to induce sedation and respiratory depression. Excessive sedation in the early post-operative period is associated with depression of the respiratory system, which can, in some cases, be fatal.



Nausea in female patients



It is well established that female patients undergoing surgery have a higher risk of experiencing nausea and vomiting in the post-operative period. New data analysing the female patient group (approximately 70% of the patients in the M6G022 Phase III clinical trial) showed a statistically significant reduction in nausea in the period 624 hours after treatment (p=0.034). The overall incidence and severity of post-operative nausea in the M6G arm for both males and females was 27% less than that observed in the morphine arm but narrowly missed statistical significance, p=0.052 (versus target of p<0.05), as previously reported. This was the second primary endpoint.


Chief Executive of CeNeS, commented: This further analysis of the recent Phase III trial data supports our stated goal of delivering M6G to the market as a novel analgesic for post-operative pain that has clearly defined benefits compared to morphine and other opiates. The large body of statistically significant Phase III efficacy and side effect/safety data also suggest that M6G could be uniquely positioned as an opiate analgesic for day case surgery an additional growing market to the current focus on hospital based post-operative pain.



It is estimated that at least 277 million units of injectable analgesics were used to treat pain in the United States in 2006. The US post-operative pain market is estimated to be $1.7 billion. CeNeS is confident that M6G will establish a strong position in the large global pain market.

Good news indeed. Shame its come on such a bad day for the markets otherwise I suspect the SP would have reacted more positively.

Hi Queen, not just good news GREAT news. All of a sudden "females" are having the benefits we invested in. What about males? I am sure there must be more great news to come for "males". M6G has been hell of a ride for the last 5 years and I sure it will be for time to come. Mind, I wouldn't be against one of these hedge funds coming in at 60p a share!

Queenie ... its a crock of sh*te imo .

Regards

Dildo - just like your c*ck when the sheep are around, you just can't keep your evil, foul-smelling opinions to yourself can you. But thanks for such an informative post, it's added immeasurable substance and depth to the thread.

Regards

Hey, nice one Queenie!

Merci parthus

Just had another look Queenie and your p*ssing in the wind mate.

Go and buy something tidy for once in you life.

Regards

xxx

Dilbert it's taken you 2 whole days to come up with that response. Is that really the best you could do?! Perhaps the sheep on the top field weren't playing the game and kept running for cover. Either way, as ever your insightful commentary has kept myself and other posters glued to the edge of their keyboards and we thank you for your infinite wisdom.

No probs mate , just ask I'm always willing to help a dickhead .

Again Dil-ute, such economy of word, such eloquent turn of phrase.

And I've noticed you've followed me onto the BIFF thread as well - anywhere in fact that I seem to post. And the thing I don't understand is that I'm not even wearing wool.

does anyone have access to information on institution holdings compared to issued shares please?

FYI. Substantial shareholdings

Avlar Bioventures Fund II 26,807,760 6.5
Gandhara Capital Master Fund Limited 26,252,626 6.4
UBS AG 22,146,632 5.4
R G Robb 17,000,000 4.1
Alan Goodman 15,843,866 3.9
GlaxoSmithKline plc 13,284,508 3.2

http://www.cenes.com/investor/financial_reports.htm

Thanks johnny

And some more positive news:-

Cambridge, UK, 20th June 2007 - CeNeS Pharmaceuticals plc (AIM: CEN), the Cambridge based biopharmaceutical company today announces new data on its short-acting sedative, CNS 7056. These preclinical data show that CNS 7056 induces deep sedation, has a rapid onset of action and rapid offset of action with predictable effects over a wide range of doses. On the basis of this successful outcome, the compound will be developed for the indications of induction and maintenance of anaesthesia in addition to sedation for day-case procedures. CeNeS also announces that the first full academic paper on CNS 7056 will be published in the July issue of the leading journal Anesthesiology. The paper is one of a small number highlighted in the introductory section of this issue.


Additional indications

Following the successful completion of studies at the University of Adelaide and under a material transfer agreement with an International Pharmaceutical company, CeNeS will develop CNS 7056 for the induction and maintenance of anaesthesia in addition to the existing development for sedation during day-case procedures. These latest pre-clinical studies show that CNS 7056 has the desirable features for an anaesthetic drug of inducing deep sedation rapidly and controllably, with predictable effects over a wide range of doses and a rapid recovery.


Academic publication

CeNeS is pleased to note that the first full academic paper on CNS 7056 will be published in the July issue of the leading international Journal Anesthesiology and has been selected as a featured article for the section this month in Anesthesiology.



Neil Clark, Chief Executive of CeNeS commented: CNS 7056 shows an excellent profile in preclinical studies. Development for the additional indications of the induction and maintenance of anaesthesia means that the market potential is significantly larger. We believe that the peak sales opportunity for this compound is now doubled to 400m. We are looking forward to filing an IND for this compound in the next few months and commencing Phase I clinical trials.

CNS 7056 exemplifies CeNeS strategy of focussing on low-risk programmes that provide early and simple proof of concept in clinical trials. Indeed, an important feature of this development programme is that we will be able to generate proof of concept data on sedation/anaesthesia in Phase I volunteer studies rather than having to wait for Phase II patient studies as is the case for most drug development programmes.

Barclays let me have another tranche at 5.11p this morning --- sub mid price.

So all the 5.11 and 5.12 deals are most likely to be purchases today. I guess they knew there was a 4.2m line coming along....

There has been some positive news recently but sp is still heading south. Why? The chairman at the end of RNS this morning said "our stated aim of partnerning our lead product is going as planned". I suppose the sp will not be changing direction until a licensing deal is struck. Does anyone have any idea when the sp is going to break through 8 or 9p?

When they strike a deal, or rumour of an impending deal hits the streets. Very hit and miss these R&D druggies, but if any of their development drugs become fully commercialsed and M6G certainly has a fighting chance, 8/9p will be but a distant memory. Shit or bust when investing in this sector and it can take years of patience to see a return on investment, but if there is a return, it can be pretty spectacular. Stick 'em in the bottom drawer and forget all about them, unless you need the funds for summat else.

pth

These must be a bargain at these prices?

CYNIC where are you?

These must be a bargain at these prices?

CYNIC where are you?

They are placing over 6 million of shares at a price of 3.5p and next chart support is around 2p.

I'm no guru but I wouldn't touch them at this price.

Dil,i will watch with interest and if they hit 2p,i will BUY!.

Price getting clobbered now capetown , wise to wait.

Have put a buy order 2p limit,doubt it will fall as far,but for once i will wait and see.

more to the point, why would you buy? ...... no obvious reason that i can see

Well Barclays seems to like them ;o)

HOLDING IN COMPANY



The Company was informed on 27 July 2007 that Barclays PLC had a total interest
in 67,888,117 ordinary shares of 1p each in the capital of the Company. This
shareholding represents 14.03 per cent. of the issued share capital of the
Company.